Healthcare
Inhibikase Therapeutics, Inc.(IKT)
Live Price
Offline$1.83
+8.93% today
1Y Change
+0.60%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $130.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +57.8%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Inhibikase Therapeutics, Inc. (IKT) is a Healthcare stock with a market cap of $130.00M and listed on NASDAQ. The stock last traded around $1.83 and up 0.6% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +57.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +57.8%, free cash flow -45.1% with operating margin 0.0% and ROIC -26.6%. Stock Foundry combines IKT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +57.8%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -2.1% | -11.6% | -12.1% |
2026 Mar 26, 2026 | +25.0% | +3.1% | +10.4% | +15.3% |
2025 Nov 14, 2025 | +0.0% | -0.7% | -2.6% | +5.9% |
Benchmark Edge
IKT vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IKT
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IKT Max Drawdown
-30.20%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IKT and SPY.
Company Overview
Inhibikase Therapeutics, Inc.
NASDAQ Capital Market
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
- Leadership
- Mark T. Iwicki
- IPO Date
- Dec 23, 2020
- Employees
- 15
- Street Address
- 3350 Riverwood Parkway SE
- Mailing
- Atlanta, GA, 30339
- Region
- Atlanta, GA, US
- Reporting Currency
- USD
- Investor Line
- 678 392 3419
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.1
- Price/Sales
- โ
- Price/Book
- 1.1
Growth
- Revenue
- 0.0%
- EPS
- +57.8%
- Free Cash Flow
- -45.1%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -46.9%
- ROIC
- -26.6%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 21.70
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.